We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

75 hedge funds and large institutions have $229M invested in Global Blood Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 14 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

176,150% more call options, than puts

Call options by funds: $17.6M | Put options by funds: $10K

157% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 14

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

10% more funds holding

Funds holding: 68 → 75 (+7)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

51% less capital invested

Capital invested by funds: $470M → $229M (-$241M)

Holders
75
Holders Change
+7
Holders Change %
+10.29%
% of All Funds
2%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
20
Increased
36
Reduced
14
Closed
13
Calls
$17.6M
Puts
$10K
Net Calls
+$17.6M
Net Calls Change
+$17.6M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$5.89M
2
ACA
Avoro Capital Advisors
New York
+$3.7M
3
BBA
Baker Bros. Advisors
New York
+$3.55M
4
IHM
Iguana Healthcare Management
New York
+$2.49M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$14.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$10.3M
3
GGHC
Gilder Gagnon Howe & Co
New York
-$9.6M
4
RG
Redmile Group
California
-$7.07M
5
SM
Sabby Management
Florida
-$3.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$72.5M +$102K +5,730 +0.1%
PA
2
Perceptive Advisors
New York
$20.6M +$1.97M +110,838 +9%
DM
3
Deerfield Management
New York
$18.9M +$533K +30,000 +3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$13.2M +$5.89M +331,365 +66%
JHIU
5
Janus Henderson Investors US
Colorado
$12.3M +$1.41M +79,073 +11%
PHS
6
PFM Health Sciences
California
$11.8M +$693K +38,999 +6%
BBA
7
Baker Bros. Advisors
New York
$9.52M +$3.55M +200,000 +50%
FCMI
8
Foresite Capital Management III
California
$7.88M +$657K +37,000 +8%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$6.7M -$10.3M -577,946 -58%
IHM
10
Iguana Healthcare Management
New York
$3.96M +$2.49M +140,000 +127%
Jennison Associates
11
Jennison Associates
New York
$3.76M -$1.34M -75,505 -24%
ACA
12
Avoro Capital Advisors
New York
$3.3M +$3.7M +208,086 New
RI
13
RTW Investments
New York
$3.03M +$281K +15,825 +9%
JP Morgan Chase
14
JP Morgan Chase
New York
$2.95M -$26.7K -1,500 -0.8%
VMI
15
VHCP Management II
New York
$2.7M +$510K +28,701 +20%
BFA
16
BlackRock Fund Advisors
California
$2.65M -$70K -3,939 -2%
EAM
17
Eventide Asset Management
Massachusetts
$2.62M – – –
DCM
18
Driehaus Capital Management
Illinois
$2.31M -$986K -55,468 -28%
SM
19
Sabby Management
Florida
$2.17M -$3.66M -205,857 -60%
UBS Group
20
UBS Group
Switzerland
$2.1M -$1.48M -83,222 -39%
Goldman Sachs
21
Goldman Sachs
New York
$2.04M +$1.85M +104,139 +421%
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$1.78M +$2M +112,300 New
CC
23
Casdin Capital
New York
$1.67M +$711K +40,000 +62%
State Street
24
State Street
Massachusetts
$1.49M +$102K +5,764 +7%
SIM
25
Spark Investment Management
New York
$1.44M +$826K +46,500 +105%
1
2 3 4

GBT Hedge Fund Activity: Q1 2016 in Review

75 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2016, worth a combined $229M — down 51% from $470M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new GBT positions and 13 closed out — a net gain of 7 holders — while 36 added to existing stakes and 14 trimmed.

The largest buyer was Vanguard Group, adding an estimated $5.89M. The largest seller was RA Capital Management, exiting entirely with an estimated $14.8M sold.

  • 75 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2016, up from 68 in Q4 2015.
  • Funds reported $229M of Global Blood Therapeutics, Inc. stock for Q1 2016, down 51% quarter-over-quarter.
  • 20 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2016 and 13 closed out, a net change of +7 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q1 2016 was Vanguard Group, an estimated $5.89M added.
  • The largest Global Blood Therapeutics, Inc. seller in Q1 2016 was RA Capital Management, an estimated $14.8M sold.

Based on aggregated 13F filings for Q1 2016.